Indoco Remedies Limited (BOM:532612)
India · Delayed Price · Currency is INR 202.35
-3.10 (-1.51%)
At close: Feb 13, 2026
Indoco Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 17,446 | 16,649 | 18,173 | 16,686 | 15,408 | 12,415 |
Other Revenue | 153.6 | - | - | - | - | - |
Revenue | 17,599 | 16,649 | 18,173 | 16,686 | 15,408 | 12,415 |
Revenue Growth (YoY) | 2.06% | -8.38% | 8.91% | 8.30% | 24.10% | 12.20% |
Cost of Revenue | 5,641 | 5,556 | 6,204 | 5,661 | 4,946 | 3,842 |
Gross Profit | 11,958 | 11,094 | 11,969 | 11,025 | 10,461 | 8,574 |
Selling, General & Admin | 5,545 | 5,259 | 4,618 | 3,941 | 3,421 | 3,176 |
Research & Development | 791.72 | 760.12 | 971.57 | 809.7 | 746.42 | 597.04 |
Other Operating Expenses | 4,701 | 4,075 | 3,925 | 3,399 | 3,001 | 2,390 |
Operating Expenses | 12,265 | 11,232 | 10,435 | 8,856 | 7,954 | 7,059 |
Operating Income | -306.9 | -138.5 | 1,534 | 2,169 | 2,507 | 1,514 |
Interest Expense | -900.99 | -620.29 | -349.3 | -237.5 | -164.58 | -210.41 |
Interest & Investment Income | 8.46 | 8.46 | 39.59 | 5.85 | 4.77 | 7.95 |
Currency Exchange Gain (Loss) | -22.18 | -22.18 | 9.82 | 2.43 | 32.9 | -1.62 |
Other Non Operating Income (Expenses) | 16.7 | 17.3 | 10.26 | 0.33 | 8.57 | 12.42 |
EBT Excluding Unusual Items | -1,205 | -755.22 | 1,244 | 1,941 | 2,388 | 1,322 |
Gain (Loss) on Sale of Investments | 6.59 | 6.59 | 2.44 | - | - | - |
Gain (Loss) on Sale of Assets | -5.02 | -5.02 | -3.78 | -12.62 | -5.11 | -2.43 |
Asset Writedown | - | - | - | - | -17.47 | - |
Other Unusual Items | -66.76 | 9.94 | 115.28 | - | - | - |
Pretax Income | -1,270 | -743.71 | 1,358 | 1,928 | 2,366 | 1,320 |
Income Tax Expense | -106.69 | 35.81 | 387.95 | 505.41 | 817.72 | 389.52 |
Earnings From Continuing Operations | -1,163 | -779.51 | 970.04 | 1,423 | 1,548 | 930.46 |
Minority Interest in Earnings | 24.54 | 42.14 | 14.56 | - | - | - |
Net Income | -1,139 | -737.37 | 984.6 | 1,423 | 1,548 | 930.46 |
Net Income to Common | -1,139 | -737.37 | 984.6 | 1,423 | 1,548 | 930.46 |
Net Income Growth | - | - | -30.78% | -8.11% | 66.37% | 285.80% |
Shares Outstanding (Basic) | 97 | 92 | 92 | 92 | 92 | 92 |
Shares Outstanding (Diluted) | 97 | 92 | 92 | 92 | 92 | 92 |
Shares Change (YoY) | 13.56% | -0.07% | 0.01% | 0.11% | - | - |
EPS (Basic) | -11.75 | -8.00 | 10.68 | 15.44 | 16.80 | 10.10 |
EPS (Diluted) | -11.75 | -8.00 | 10.67 | 15.42 | 16.80 | 10.10 |
EPS Growth | - | - | -30.79% | -8.21% | 66.37% | 285.80% |
Free Cash Flow | - | -2,612 | -2,706 | -284.23 | 485.04 | 53.73 |
Free Cash Flow Per Share | - | -28.33 | -29.33 | -3.08 | 5.26 | 0.58 |
Dividend Per Share | - | 0.200 | 1.500 | 2.250 | 1.500 | 1.500 |
Dividend Growth | - | -86.67% | -33.33% | 50.00% | - | 400.00% |
Gross Margin | 67.95% | 66.63% | 65.86% | 66.07% | 67.90% | 69.06% |
Operating Margin | -1.74% | -0.83% | 8.44% | 13.00% | 16.27% | 12.20% |
Profit Margin | -6.47% | -4.43% | 5.42% | 8.53% | 10.05% | 7.49% |
Free Cash Flow Margin | - | -15.69% | -14.89% | -1.70% | 3.15% | 0.43% |
EBITDA | 984.55 | 852.29 | 2,124 | 2,719 | 2,999 | 2,006 |
EBITDA Margin | 5.59% | 5.12% | 11.68% | 16.30% | 19.46% | 16.16% |
D&A For EBITDA | 1,291 | 990.79 | 589.92 | 549.88 | 492.24 | 492.15 |
EBIT | -306.9 | -138.5 | 1,534 | 2,169 | 2,507 | 1,514 |
EBIT Margin | -1.74% | -0.83% | 8.44% | 13.00% | 16.27% | 12.20% |
Effective Tax Rate | - | - | 28.57% | 26.21% | 34.56% | 29.51% |
Revenue as Reported | 17,653 | 16,704 | 18,271 | 16,709 | 15,431 | 12,446 |
Advertising Expenses | - | 1,318 | 999.09 | 715.66 | 458.47 | 435.49 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.